



**Georgina V Long**

**Contact**

Georgina V Long

## Publications (5)

Schmitt C, Hoefsmit E, Fangmeier T, Kramer N, Kabakci C, González-Navajas J, Versluis J, Compter A, Harrer T, Mijočević H, Schubert S, Hundsberger T, Menzies A, Scolyer R, Long G, French L, Blank C, Heinzerling L. Immune checkpoint inhibitor-induced neurotoxicity is not associated with seroprevalence of neurotropic infections. *Cancer Immunol Immunother* 2023

Müller-Jensen L, Zierold S, Versluis J, Boehmerle W, Huehnchen P, Endres M, Mohr R, Compter A, Blank C, Hagenacker T, Meier F, Reinhardt L, Gesierich A, Salzmann M, Hassel J, Ugurel S, Zimmer L, Banks P, Spain L, Soon J, Enokida T, Tahara M, Kähler K, Seggewiss-Bernhardt R, Harvey C, Long G, Schöberl F, von Baumgarten L, Hundsberger T, Schlaak M, French L, Knauss S, Heinzerling L. Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis. *Data Brief* 2022; 45:108649.

Müller-Jensen L, Zierold S, Versluis J, Boehmerle W, Huehnchen P, Endres M, Mohr R, Compter A, Blank C, Hagenacker T, Meier F, Reinhardt L, Gesierich A, Salzmann M, Hassel J, Ugurel S, Zimmer L, Banks P, Spain L, Soon J, Enokida T, Tahara M, Kähler K, Seggewiss-Bernhardt R, Harvey C, Long G, Schöberl F, von Baumgarten L, Hundsberger T, Schlaak M, French L, Knauss S, Heinzerling L. Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study. *Eur J Cancer* 2022; 175:224–235.

Garbe C, Keim U, Amaral T, Berking C, Eigenthaler T, Flatz L, Gesierich A, Leiter U, Stadler R, Sunderkötter C, Tüting T, Utikal J, Wollina U, Zimmer L, Zouboulis C, Ascierto P, Eggermont A, Grob J, Hauschild A, Sekulovic L, Long G, Luke J, Michielin O, Peris K, Schadendorf D, Kirkwood J, Lorigan P, Central Malignant Melanoma Registry (CMMR). Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. *J Clin Oncol* 2022; 40:3741–3749.

Bald T, Scolyer R, Long G, Wilmott J, Hughes B, Ahern E, Taheri T, Kristiansen G, Geyer M, Hözel M, Seo E, Batstone M, Landsberg J, Smyth M, Martinet L, Johnston R, Möller A, Nicholson S, Veillette A, Dougall W, Flatz L, Pop O, Dietrich D, Nakamura K, Casey M, Koufariotis L, Li R, Li K, Meza Guzman L, Lima L, Das I, Krumeich S, Stannard K, Corvino D, Sundarrajah A, Aguilera A, Salim N, Jorge M, Quine B, Effern M, Jacquelin S, Madore J, Pearson S, Raghavendra A, Lepletier A, Vari F, Kelly G, Ham S, Braun M. CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8 T Cells. *Immunity* 2020; 53:805–823.e15.

## Projects (0)

No results found.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)